Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma
| Autor: | Thomas W. Flaig, Sara Trigero, Maria T Bourlon, Julia Clemons, Elaine T. Lam, Dexiang Gao |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Sorafenib
Cancer Research Pathology medicine.medical_specialty medicine.diagnostic_test business.industry Sunitinib Macrocytosis urologic and male genital diseases medicine.disease Gastroenterology Oncology Renal cell carcinoma Chart review Internal medicine medicine Clinical significance In patient business Mean corpuscular volume medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 33:453-453 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 453 Background: Increases in mean corpuscular volume (MCV) and hypothyroidism have been observed in patients on sunitinib treatment. We characterized tyrosine kinase-associated macrocytosis in metastatic renal cell carcinoma (mRCC) patients and its relationship, along with thyroid dysfunction, to progression-free survival (PFS). Methods: A retrospective chart review was performed on patients treated with sunitinib and/or sorafenib (01/2005-01/2011). Data pertaining to the development of macrocytosis was analyzed in association with our previous data on thyroid dysfunction in these patients. We assessed PFS, as clinically defined by the treating provider. Results: Seventy-four patients with 103 treatment periods for sorafenib (47) and sunitinib (56) were analyzed. Macrocytosis was found in 55% and 8% of sunitinib and sorafenib treatment periods, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|